← Leaderboards
Andrew M Davidoff
St. Jude Children'S Research Hospital
$14,340,525
Attributed
$16,843,101
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2005–22$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$16,843,101 · 6
By mechanism
R01$15,491,587 · 5
P01$1,351,514 · 1
Top collaborators
- Lawrence M Pfeffer5 shared
- Taosheng Chen4 shared
- Stephen W White4 shared
- Jun Yang4 shared
Most similar at St. Jude Children'S Research Hospital
Same institution · by research overlap
- Gerard Paul Zambetti$5,606,007
- Taosheng Chen$8,225,244
- Jun Yang$3,072,061
- Charles G. Mullighan$25,123,215
- Zoran Rankovic$1,675,492
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsBasePre-ClinicalProteinsDoseMediatingResponseFutureMalignant NeoplasmsHemophilia BNonhuman PrimateInhibitor/AntagonistInsightGene TransferRecombinant Adeno-Associated Virus (Raav)HemorrhageAffectSafetyLiverFactor IxAdeno-Associated Viral VectorMacaca MulattaSerotypingToxic Effect
Grant awards (34)
Clinical trial of AAV8-mediated FVIII gene transfer for hemophilia A$669,282
R01 · FY2022 · HL · contact PI
Clinical trial of AAV8-mediated FVIII gene transfer for hemophilia A$669,282
R01 · FY2021 · HL · contact PI
Development of small molecules to target KDM4B$410,606
R01 · FY2021 · CA
Clinical trial of AAV8-mediated FVIII gene transfer for hemophilia A$669,282
R01 · FY2020 · HL · contact PI
Development of small molecules to target KDM4B$410,606
R01 · FY2020 · CA
Clinical trial of AAV8-mediated FVIII gene transfer for hemophilia A$615,432
R01 · FY2019 · HL · contact PI
Development of small molecules to target KDM4B$398,287
R01 · FY2019 · CA
Clinical trial of AAV8-mediated FVIII gene transfer for hemophilia A$561,582
R01 · FY2018 · HL · contact PI
Development of small molecules to target KDM4B$410,606
R01 · FY2018 · CA
AAV-Mediated Gene Therapy for Hemophilia$533,454
R01 · FY2015 · HL · contact PI
AAV-Mediated Gene Therapy for Hemophilia$522,961
R01 · FY2014 · HL · contact PI
Clinical trial of self complementary AAV8-mediated gene transfer for hemophilia B$607,042
R01 · FY2013 · HL · contact PI
AAV-Mediated Gene Therapy for Hemophilia$508,019
R01 · FY2013 · HL · contact PI
Strategies to improve the antiglioma action of IFN-?: a role for NF-kB inhibition$477,152
R01 · FY2013 · CA
Clinical trial of self complementary AAV8-mediated gene transfer for hemophilia B$652,476
R01 · FY2012 · HL · contact PI
AAV-Mediated Gene Therapy for Hemophilia$545,594
R01 · FY2012 · HL · contact PI
Strategies to improve the antiglioma action of IFN-?: a role for NF-kB inhibition$505,966
R01 · FY2012 · CA
Clinical trial of self complementary AAV8-mediated gene transfer for hemophilia B$782,602
R01 · FY2011 · HL · contact PI
AAV-Mediated Gene Therapy for Hemophilia$548,387
R01 · FY2011 · HL · contact PI
Strategies to improve the antiglioma action of IFN-?: a role for NF-kB inhibition$510,612
R01 · FY2011 · CA
ANGIOGENESIS INHIBITORS IN THE MULTIMODAL TREATMENT OF PEDIATRIC SOLID TUMORS$263,764
P01 · FY2011 · CA · contact PI
Clinical trial of self complementary AAV8-mediated gene transfer for hemophilia B$780,538
R01 · FY2010 · HL · contact PI
Strategies to improve the antiglioma action of IFN-?: a role for NF-kB inhibition$531,332
R01 · FY2010 · CA
ANGIOGENESIS INHIBITORS IN THE MULTIMODAL TREATMENT OF PEDIATRIC SOLID TUMORS$284,868
P01 · FY2010 · CA · contact PI
Clinical trial of self complementary AAV8-mediated gene transfer for hemophilia B$827,663
R01 · FY2009 · HL · contact PI
Strategies to improve the antiglioma action of IFN-?: a role for NF-kB inhibition$534,932
R01 · FY2009 · CA
rAAV-Mediated Gene Therapy for Hemophillia B$355,568
R01 · FY2009 · HL · contact PI
ANGIOGENESIS INHIBITORS IN THE MULTIMODAL TREATMENT OF PEDIATRIC SOLID TUMORS$280,983
P01 · FY2009 · CA · contact PI
rAAV-Mediated Gene Therapy for Hemophillia B$355,568
R01 · FY2008 · HL · contact PI
ANGIOGENESIS INHIBITORS IN THE MULTIMODAL TREATMENT OF PEDIATRIC SOLID TUMORS$274,288
P01 · FY2008 · CA · contact PI
rAAV-Mediated Gene Therapy for Hemophillia B$355,568
R01 · FY2007 · HL · contact PI
ANGIOGENESIS INHIBITORS IN THE MULTIMODAL TREATMENT OF PEDIATRIC SOLID TUMORS$247,611
P01 · FY2007 · CA · contact PI
rAAV-Mediated Gene Therapy for Hemophillia B$366,188
R01 · FY2006 · HL · contact PI
rAAV-Mediated Gene Therapy for Hemophillia B$375,000
R01 · FY2005 · HL